OBJECTIVE—We prospectively examined plasma levels of leptin and soluble leptin receptor (sOB-R), as well as their interactions with other diabetes risk factors, in relation to type 2 diabetes to elucidate the complex relation between these two biomarkers and diabetes risk.

RESEARCH DESIGN AND METHODS—Of 32,826 Nurses’ Health Study participants who provided blood samples during 1989–1990, 1,054 incident case subjects of type 2 diabetes were identified and confirmed during 1990–2004 and 1,254 matched control subjects were selected. Plasma leptin and sOB-R levels were measured among these participants.

RESULTS—After multivariate adjustment for BMI, lifestyle practices, and dietary factors, sOB-R levels were significantly associated with a lower risk of type 2 diabetes. In comparison with women in the lowest quintile, the ORs (95% CI) of developing type 2 diabetes were 0.73 (0.55–0.96), 0.51 (0.38–0.68), 0.42 (0.31–0.57), and 0.39 (0.28–0.54; P for trend < 0.0001) for women in the second to fifth quintiles of sOB-R levels, respectively. In contrast, plasma leptin levels were not significantly associated with the risk of type 2 diabetes: The OR (95% CI) was 0.82 (0.62–1.01; P for trend = 0.46) comparing the highest with the lowest quintile of leptin levels. sOB-R levels were consistently associated with a decreased risk of type 2 diabetes at various levels of leptin or high-molecular-weight adiponectin.

CONCLUSIONS—These data suggest a strong inverse association between plasma sOB-R levels and risk of type 2 diabetes, independent of BMI, leptin, and adiponectin levels. Diabetes 59: 611–618, 2010

L

epitin, a 16-kDa protein produced primarily in adipose tissue (1), is a pleiotropic hormone that is involved in body weight regulation, puberty, reproduction, and immune function (2–4). Although accumulating evidence suggests that leptin may also directly interact with insulin on glucose metabolism (3), conflicting results have been generated for the effects of leptin on insulin sensitivity in animal models and humans (5) and for circulating leptin levels in relation to type 2 diabetes in humans (6–14). These mixed results indicate that other regulatory factors may modulate the effects of leptin on insulin sensitivity or diabetes. Soluble leptin receptors (sOB-Rs) that provide the primary leptin-binding capacity in human circulation (15) have been suggested to be such a modulating factor because sOB-R acts as a buffer to maintain the bioavailability of free leptin in the circulation (16). Interestingly, several cross-sectional studies consistently showed that sOB-R was inversely correlated with adiposity and insulin resistance indexes in humans (17–20). However, no prospective data exist regarding the association between sOB-R and type 2 diabetes risk or the joint effects with leptin on diabetes risk. Therefore, we performed a prospective case-control study in the Nurses’ Health Study (NHS) cohort to examine the associations among leptin, sOB-R, and risk of type 2 diabetes in U.S. women.

RESEARCH DESIGN AND METHODS

The NHS cohort was established in 1976 with 121,700 female registered nurses aged 30–55 years who were residing in 11 U.S. states and had completed a mailed questionnaire on their medical history and lifestyle characteristics. During 1989–1990, upon request, 32,826 women provided blood samples, the majority (97%) of which were received within 26 h of blood draw. Immediately upon arrival, whole blood samples were centrifuged and aliquoted into cryotubes as plasma, buffy coat, and erythrocytes, which were then stored in the vapor phase of liquid nitrogen freezers at a temperature ≤ −130°C.

Among the participants who provided blood samples and were free of diabetes, cardiovascular disease, and cancer at blood draw, we prospectively identified and confirmed 1,054 type 2 diabetes case subjects from the date of blood draw through June 2004. Using risk-set sampling, one or two control subjects were randomly selected for each case subject from the rest of the population who remained free of diabetes and matched to case subjects by age at blood draw (±1 year), date of blood draw (±3 months), fasting status (fasting for ≥8 h or not fasting), and race. After excluding eight control subjects with missing leptin or sOB-R data, 1,054 incident type 2 diabetes case subjects and 1,254 control subjects were available for the current analysis.

The study protocol was approved by the institutional review board of the Brigham and Women’s Hospital and the Human Subjects Committee Review Board of Harvard School of Public Health.

Ascertainment of type 2 diabetes. In the NHS, women who reported a diagnosis of type 2 diabetes in the biennial follow-up questionnaires were sent supplementary questionnaires inquiring about symptoms, diagnostic tests, and
treatment for the purpose of confirmation. The self-report of diagnosis of type 2 diabetes has been proven to be accurate in a validation study (21). Of a random sample of 62 diabetic nurses initially confirmed by the supplementary questionnaire, 61 (98%) were confirmed by medical records reviewed by an endocrinologist blinded to the supplementary questionnaire information (21). In the current study, all case subjects were confirmed using the supplementary questionnaire. For case subjects diagnosed before 1998, we used the following criteria from the National Diabetes Data Group for the confirmation of type 2 diabetes diagnosis: 1) an elevated glucose concentration (fasting plasma glucose ≥7.8 mmol/l, random plasma glucose ≥11.1 mmol/l, or plasma glucose ≥11.1 mmol/l after an oral glucose load) and at least one symptom (excessive thirst, polyuria, weight loss, or hunger) related to diabetes; 2) no symptoms on glucose concentration on a diabetes drug or treatment with insulin or oral hypoglycemic medication. For case subjects of type 2 diabetes identified after 1998, the cutoff point used for fasting plasma glucose concentrations was lowered to 7.0 mmol/l according to the American Diabetes Association criteria.

**Laboratory procedures.** Each case-control pair or triplet was shipped in the same batch and analyzed in the same run. Within each batch, samples were assayed by the same technicians in a random sequence under identical conditions.

Total leptin was measured by a radioimmunoassay (Millipore, Billerica, MA), the sensitivity of which is 0.5 ng/ml. SOB-R was measured by ELISA technique (R&D Systems, Minneapolis, MN) with a sensitivity of 0.06 ng/ml. Laboratory control samples (n = 20) were run along with the case-control samples in each run. In the measurements of these control samples, the average intra-assay coefficient of variation was 7.7% for the leptin assay and 7.3% for the SOB-R assay. In addition to leptin and SOB-R, total and high-molecular-weight (HMW) adiponectin, resistin, C-reactive protein, tumor necrosis factor-α receptor 2, interleukin-6 (IL-6), interleukin-18 (IL-18), fasting insulin, and C-peptide were also measured for all or some of the case and control subjects.

The assays for these biomarkers have been described elsewhere (22–24).

**Assessment of lifestyle and dietary covariates.** In baseline and/or subsequent biennial follow-up questionnaires, information on major lifestyle risk factors for chronic diseases, such as body weight, cigarette smoking, physical activity, family history of diabetes, menopausal status, and postmenopausal hormone use, was collected and updated in the NIH cohort. BMI as weight in kilograms divided by the square of height in meters (kg/m²) was calculated to assess overall adiposity. We asked the participants to measure their waist circumference (at umbilicus) and hip circumference (the largest circumference or waist-to-hip ratio). Significantly positive associations with insulin but significant correlations for leptin and resistin; the OR (95% CI) was 0.67 (0.47–0.95; r = 0.43). To better control for confounding by BMI, we used BMI-adjusted residuals of these biomarkers in the subsequent analyses. BMI-adjusted leptin and SOB-R were not correlated with waist circumference or waist-to-hip ratio. Significantly positive correlations were found between leptin and C-reactive protein (r = 0.25) and between SOB-R and HMW adiponectin (r = 0.26). In a subset of the control subjects with insulin and C-peptide data, we found no significant correlations with insulin but significant correlations for leptin (r = 0.18) and SOB-R (r = −0.18) with C-peptide.

After multivariate adjustment for established and potential lifestyle and dietary risk factors for type 2 diabetes, BMI-adjusted leptin levels were not significantly associated with diabetes risk (Table 3). In contrast, BMI-adjusted SOB-R levels were significantly associated with a lower risk of type 2 diabetes. Compared with women in the lowest quintile of SOB-R, women in the highest quintile had an OR of 0.39 (95% CI: 0.28–0.54; P for trend < 0.0001). This association was attenuated but remained statistically significant after further adjustment for HMW adiponectin; the OR (95% CI) was 0.67 (0.47–0.95; P for trend = 0.005). Further adjustment for other biomarkers, including inflammatory markers and other adipokines, did not change the point estimates of these associations materially, although the 95% CIs were much wider and P values less significant because only half of the study population had all of these biomarkers available (data not shown).

**RESULTS**

Table 1 shows the baseline characteristics of study population. As expected, type 2 diabetes case subjects had a higher BMI, lower physical activity levels, higher probability of having family history of diabetes, and less healthy dietary intake at baseline than control subjects. Case subjects also had significantly higher leptin levels but lower SOB-R levels than control subjects. The distribution of other inflammatory biomarkers and adipokines in case and control subjects was consistent with our previous findings (22–24).

In control subjects, after adjustment for multiple covariates, plasma leptin levels were strongly correlated with BMI; the partial Spearman correlation coefficient (r) was 0.72 (Table 2). In contrast, SOB-R was significantly inversely correlated with BMI (r = −0.43). To better control for confounding by BMI, we used BMI-adjusted residuals of these biomarkers in the subsequent analyses. BMI-adjusted leptin and SOB-R were not correlated with waist circumference or waist-to-hip ratio. Significantly positive correlations were found between leptin and C-reactive protein (r = 0.25) and between SOB-R and HMW adiponectin (r = 0.26). In a subset of the control subjects with insulin and C-peptide data, we found no significant correlations with insulin but significant correlations for leptin (r = 0.18) and SOB-R (r = −0.18) with C-peptide.
spline regression models; the $P$ value for nonlinearity is 0.35 (Fig. 1).

Joint associations for sOB-R and leptin, as well as HMW adiponectin, receptor, and IL-18, are shown in Fig. 2. We did not find a significant interaction between sOB-R and leptin ($P$ for interaction $= 0.09$) or HMW adiponectin ($P$ for interaction $= 0.30$). Within each tertile of leptin levels, sOB-R levels were consistently associated with a lower risk of type 2 diabetes. In our previous study, HMW adiponectin was significantly associated with a lower risk of type 2 diabetes (24). In the current analysis, sOB-R was associated with a lower risk within each HMW adiponectin level and vice versa. Women who were in the highest tertiles of both sOB-R and HMW adiponectin had the lowest odds of developing type 2 diabetes; the OR (95% CI) was 0.13 (0.09–0.20) in comparison with women in the lowest tertiles of these two markers.

We subsequently examined potential interactions of leptin biomarkers with other risk factors in relation to type 2 diabetes risk (Table 4). Although we did not find significant interactions between leptin biomarkers and risk factors such as age, fasting status, and physical activity, the association for leptin with diabetes risk was significantly modified by BMI ($P$ for interaction $= 0.001$). Leptin was significantly associated with a lower risk of type 2 diabetes in participants with a BMI $\geq$30 kg/m². In contrast, in lean participants (BMI $<25$ kg/m²), leptin levels were associated with a significantly increased risk of type 2 diabetes. Additional adjustment for waist circumference or waist-to-hip ratio did not change these associations (data not shown).

**DISCUSSION**

In this nested case-control study conducted in middle-aged U.S. women, we found that high sOB-R levels were
strongly associated with a lower risk of type 2 diabetes independent of baseline leptin or adiposity levels. On the other hand, BMI-adjusted leptin levels were not significantly associated with risk of type 2 diabetes.

Our study provided the first piece of evidence for an inverse association between sOB-R levels and risk of developing type 2 diabetes independent of plasma leptin levels. Leptin generates its central and peripheral effects by binding to its receptors on the cell surface and subsequently activating downstream signaling pathways (29). Through posttranscriptional alternative RNA splicing, several isoforms of leptin receptors with identical extracellular and transmembrane domains but variable intracellular domains are expressed in humans (30). The long form of leptin receptor with the full length of intracellular domain is expressed primarily in the hypothalamus, whereas the short forms of leptin receptor (OB-Rs) are expressed primarily in peripheral tissues (30). sOB-R, a special leptin receptor with the extracellular domain only, is formed by ectodomain shedding of leptin receptors on the cell surface (31), and provides the primary binding capacity in human circulation (15). The function of sOB-R is not entirely clear but believed to delay the clearance of leptin from the circulation and, thus, increase leptin’s availability (16). In addition, there is evidence suggesting that sOB-R not only alters the clearance of leptin but also potentiates leptin action (32). This is an analogy to the observation that the action of IL-6 can be boosted by binding to its soluble receptor (33), which shares a homologous structure with leptin receptor (34). Furthermore, because sOB-R levels are highly correlated with the cell surface expression of leptin receptors (r = 0.80) (35), especially OB-Rb, sOB-R may represent the total amount or biological activity of OB-Rs expressed in peripheral tissues. Unlike long form of leptin receptor, OB-Rb does not contain the intracellular motifs required to activate the Janus kinase/signal transducers and activators of transcription signaling pathway that mediates the energy homeostasis effects of leptin (36). However, accumulating evidence suggests that OB-Rb may mediate the effects of leptin on insulin sensitivity and other peripheral effects through a distinct pathway involving insulin receptor substrate/phosphatidylinositol-3-OH kinase pathway (37–41). Although more data are needed to further elucidate sOB-R’s functions, these mechanisms may underlie the inverse association with diabetes risk for sOB-R observed in the current study.

Consistent with a previous study (20), we found a significant, positive correlation between sOB-R and HMW adiponectin in the current study. Both biomarkers are correlated with lower levels of adiposity and decrease after weight loss (17,19), and their short-term variations are nearly identical (42), suggesting these two biomarkers may share some common regulatory factors. However, the inverse associations of these two biomarkers were independent of each other, and women with high levels of both biomarkers had dramatically lower risk of developing diabetes. Whether these two molecules share the same pathway or affect diabetes risk through distinct pathways warrants further investigation.

### TABLE 2
Partial Spearman correlation coefficients for anthropometric measurements, adipokines, and inflammatory markers among control subjects

|                          | Leptin (ng/ml) | sOB-R (ng/ml) |
|--------------------------|---------------|--------------|
| Age (years)              | 0.07*         | 0.11*        |
| BMI (kg/m²)              | 0.72*         | -0.43*       |
| Waist circumference (cm) | 0.07          | -0.08        |
| Waist-to-hip ratio       | -0.03         | -0.09*       |
| HMW adiponectin (µg/ml)  | -0.07†        | 0.26*        |
| Resistin (ng/ml)         | 0.06†         | -0.07†       |
| CRP (mg/dl)              | 0.25*         | 0.02         |
| TNFα-R2 (pg/ml)          | 0.06          | -0.01        |
| IL-6 (ng/ml)             | 0.08          | 0.07         |
| IL-18 (pg/ml)            | 0.04          | 0.01         |
| Insulin (µU/ml)‡         | 0.06          | -0.08        |
| C-peptide (pm/ml)‡       | 0.18*         | -0.18*       |
| Leptin (ng/ml)           | —             | -0.14*       |
| sOB-R (ng/ml)            | -0.14*        | —            |

Spearman correlation coefficients between biomarkers were adjusted for age at blood draw, date of blood draw, fasting status (8 h vs. <8 h since last meal), race, BMI (kg/m²), smoking status (never smoked, former smoker, or current smoker), postmenopausal status (yes, no), hormone use (never used, past user, current user), family history of diabetes (yes, no), physical activity and alcohol intake (both in quintiles), BMI-adjusted residuals of leptin and sOB-R were used except for the correlation with BMI. n = 1,254 for leptin, sOB-R, age, and BMI; n = 892 for waist circumference and waist-to-hip ratio; n = 1,392 for HMW, resistin, and IL-18; n = 492 for C-reactive protein (CRP), tumor necrosis factor-α receptor 2 (TNFα-R2), and IL-6. *P < 0.05. †Fasting samples only, n = 344.

### TABLE 3
ORs (95% CI) of type 2 diabetes for quintiles of plasma leptin and sOB-R levels

|                          | Q1 (lowest) | Q2 | Q3 | Q4 | Q5 (highest) | P for trend |
|--------------------------|-------------|----|----|----|--------------|------------|
| Leptin (ng/ml), median (range) | 12.7 (<15.0) | 17.2 (15.0–19.1) | 21.1 (19.2–23.3) | 26.1 (23.4–29.7) | 35.3 (>29.7) | —          |
| Case/control subjects (n) | 252/250     | 138/251 | 188/251 | 226/251 | 250/251       | —          |
| Model 2                   | 1.0         | 0.54 (0.42–0.71) | 0.77 (0.58–0.97) | 0.89 (0.71–1.05) | 0.99 (0.77–1.27) | 0.11       |
| Model 2                   | 1.0         | 0.76 (0.55–0.94) | 0.90 (0.67–1.21) | 0.95 (0.71–1.28) | 0.82 (0.62–1.10) | 0.46       |
| Model 2 + HMW adiponectin | 1.0         | 0.73 (0.52–1.02) | 0.85 (0.62–1.17) | 0.90 (0.66–1.23) | 0.80 (0.59–1.08) | 0.39       |
| sOB-R (ng/ml), median (range) | 20.4 (<22.9) | 25.0 (22.9–27.0) | 28.9 (27.1–30.8) | 33.9 (30.9–36.9) | 42.0 (>36.9) | —          |
| Case/control subjects (n) | 268/250     | 200/251 | 205/251 | 192/251 | 129/251       | —          |
| Model 1                   | 1.0         | 0.96 (0.75–1.22) | 0.76 (0.59–0.97) | 0.71 (0.55–0.92) | 0.47 (0.36–0.62) | <0.0001   |
| Model 1                   | 1.0         | 0.73 (0.59–0.96) | 0.51 (0.38–0.68) | 0.42 (0.31–0.57) | 0.39 (0.28–0.54) | <0.0001   |
| Model 2 + HMW adiponectin | 1.0         | 0.83 (0.62–1.12) | 0.62 (0.46–0.84) | 0.61 (0.44–0.84) | 0.67 (0.47–0.95) | 0.005     |

Multivariate model 1 was adjusted for matching factors only (age at blood draw, date of blood draw, fasting status [8 h vs. <8 h since last meal], and race). Model 2 was further adjusted for BMI (kg/m²), smoking status (never smoked, past smoker, or current smoker), postmenopausal status (yes, no), hormone use (never used, past user, current user), family history of diabetes (yes, no), physical activity (in quintiles), intake of alcohol, cereal fiber, heme iron, trans fat, and magnesium, and coffee and red meat consumption (all in quintiles).
Although intervention studies conducted in leptin-deficient animal models and humans supported a beneficial effect of leptin on insulin sensitivity or type 2 diabetes (43–47), prospective epidemiologic data on circulating leptin levels and future risk of type 2 diabetes have been mixed in subjects with normal leptin secretion ability (6–14). In humans, leptin levels are strongly correlated with subcutaneous adiposity, reflecting leptin resistance in obese individuals. To remove the confounding effects of BMI, we examined BMI-adjusted leptin levels in relation to diabetes risk. In our study, BMI-adjusted leptin levels were not significantly associated with diabetes risk. However, our data suggest that the association between leptin and type 2 diabetes was modulated by BMI. Leptin levels tended to be associated with a lower risk among relatively obese subjects. Two previous studies also found a similar association (8,14). One possible explanation for the positive association between leptin and diabetes risk in lean participants could be that high leptin levels reflected the amount of adipose tissue that was not captured by BMI, although further adjustment for waist circumference did not change our observation. The beneficial effects of high leptin levels on diabetes risk in overweight or obese people may be related to the peripheral effects of leptin on insulin sensitivity rather than its effects on weight regulation (5) because in the cerebrospinal fluid free leptin levels are already saturated at low levels of circulating leptin levels (48). Whether high leptin levels in lean people represent a deteriorating metabolic status needs further examination.

The current study has several strengths. The prospective study design made it unlikely that disease status or treatment may influence the leptin or sOB-R levels (i.e., that reverse causation occurred). In addition, we used
In conclusion, we found a strong, inverse association between circulating soluble leptin receptor levels and risk of type 2 diabetes, independent of obesity and leptin levels. On the other hand, the association between leptin and diabetes risk may be modified by adiposity. Biological mechanisms underlying these novel observations need to be further elucidated.

BMI-adjusted residuals of leptin biomarkers in the current analysis to more completely control for strong confounding by BMI. Other strengths include a large sample size, long follow-up period, validated approach for confirming type 2 diabetes case subjects, and adjustment for a multitude of risk factors for type 2 diabetes.

Several limitations merit discussion as well. First, in observational studies, residual confounding, especially the confounding by adiposity not captured by BMI and waist circumference in the current study, cannot be entirely ruled out. In addition, some covariates were assessed at different time points, which may lead to potentially incomplete controlling for confounding by these factors. Second, a single baseline measurement of leptin or sOB-R levels may not represent the long-term levels of these markers. However, leptin levels have been shown to be quite stable over time (49). Similar to adiponectin, the short-term variation of sOB-R levels was relatively small (50). Third, because our study sample included only middle-aged women who were predominantly white, it is unclear whether the results can be generalized to men and other ethnic groups.

In conclusion, we found a strong, inverse association between circulating soluble leptin receptor levels and risk of type 2 diabetes, independent of obesity and leptin levels. On the other hand, the association between leptin and diabetes risk may be modified by adiposity. Biological mechanisms underlying these novel observations need to be further elucidated.

### Acknowledgments

This work was supported by the National Institutes of Health and the Intramural Research Program of the National Institute of Child Health & Human Development (Grants CA-87969, DK-58845, and DK-58785). Q.S. was supported by a Unilever Postdoctoral Fellowship. J.B.M. was supported by a Career Development Award from the American Diabetes Association and Grant K24 DK-080140 from the National Institute of Diabetes and Digestive and Kidney Diseases. C.S.M. was supported by discretionary grants from the Tanita Corporation and Beth Israel Deaconess Medical Center.

J.B.M. currently has research grants from GlaxoSmithKline and sanofi-aventis and has served on consultancy boards for sanofi-aventis and Interleukin Genetics. No other potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the Scientific Sessions of the American Heart Association, Orlando, Florida, 14–18 November 2009.

### REFERENCES

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.

2. Farooqi IS, O’Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009;89:980S–984S.

3. Harris RB. Leptin—much more than a satiety signal. Annu Rev Nutr 2000;20:45–75.

### Table 4

| ORs (95% CI) of type 2 diabetes for tertiles of plasma leptin and sOB-R levels by lifestyle factors | Baseline plasma levels | P for trend | P for interaction |
|---|---|---|---|
| Leptin (ng/ml) | | | |
| Age at blood draw* | | | |
| <60 (case subject = 713, control subject = 837) | 1.0 | 0.82 (0.61–1.11) | 0.006 | — |
| ≥60 (case subject = 341, control subject = 417) | 1.0 | 1.10 (0.70–1.70) | 0.39 | — |
| Fasting status (≥ 8 h since last meal) | | | |
| Fasting (case subject = 376, control subject = 450) | 1.0 | 0.80 (0.54–1.20) | 0.70 | — |
| Nonfasting (case subject = 678, control subject = 804) | 1.0 | 1.00 (0.73–1.36) | 0.70 | — |
| BMI at baseline (kg/m²)* | | | |
| <25 (case subject = 182, control subject = 653) | 1.0 | 1.24 (0.78–1.97) | 0.04 | — |
| 25.0–29.9 (case subject = 363, control subject = 365) | 1.0 | 0.98 (0.63–1.52) | 0.47 | — |
| ≥30 (case subject = 509, control subject = 236) | 1.0 | 0.78 (0.50–1.24) | 0.02 | — |
| Physical activity at baseline (MET-h)* | | | |
| <10 (case subject = 569, control subject = 515) | 1.0 | 0.84 (0.56–1.21) | 0.68 | — |
| ≥10 (case subject = 485, control subject = 739) | 1.0 | 0.94 (0.67–1.32) | 0.86 | — |
| sOB-R (ng/ml) | | | |
| Age at blood draw* | | | |
| <60 (case subject = 713, control subject = 837) | 1.0 | 0.66 (0.50–0.88) | <0.0001 | — |
| ≥60 (case subject = 341, control subject = 417) | 1.0 | 0.49 (0.32–0.74) | 0.01 | — |
| Fasting status (≥ 8 h since last meal) | | | |
| Fasting (case subject = 376, control subject = 450) | 1.0 | 0.60 (0.41–0.89) | <0.0001 | — |
| Nonfasting (case subject = 678, control subject = 804) | 1.0 | 0.59 (0.44–0.78) | 0.0001 | — |
| BMI at baseline (kg/m²)* | | | |
| <25 (case subject = 182, control subject = 653) | 1.0 | 0.70 (0.44–1.10) | 0.006 | — |
| 25.0–29.9 (case subject = 363, control subject = 365) | 1.0 | 0.55 (0.38–0.80) | 0.002 | — |
| ≥30 (case subject = 509, control subject = 236) | 1.0 | 0.55 (0.36–0.84) | 0.001 | — |
| Physical activity at baseline (MET-h)* | | | |
| <10 (case subject = 569, control subject = 515) | 1.0 | 0.68 (0.49–0.95) | <0.0001 | — |
| ≥10 (case subject = 485, control subject = 739) | 1.0 | 0.55 (0.40–0.76) | 0.0002 | — |

Multivariate models were adjusted for the same set of covariates for model 2 in Table 3. *We further adjusted for the interacting variable in the continuous form to control for residual confounding in the stratified analysis.
6. Ley SH, Harris SB, Connell PW, Mamakeesick M, Gittelsohn J, Hegele RA, Retnakaran R, Zinman B, Hanley AJ. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 2008;31:1410–1415

5. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. Faseb J 2002;16:1163–1176

4. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763–770

3. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care 2002;25:1242–1248

2. Hu FB, Stampfer MJ, Rimm E, Ascherio A, Rosner BA, Spiegelman D, Willett WC. Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol 1999;149:531–540

1. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied Regression Analysis and Other Multivariable Methods. Boston, MA, Duxbury Press, 1998

—. DURRLEMAN S. Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551–561

—. KRONENBERG HM, MELMID S, LARSEN PR, POLONSKY KS. Williams Textbook of Endocrinology. Philadelphia, PA, Elsevier Health Sciences, 2008

—. TARTAGLIA LA. The leptin receptor. J Biol Chem 1997;272:6093–6096

—. GE H, HUANG L, POURBAHRAMI T, LI C. Generation of soluble leptin receptor by ectodomain shedding. Leptin-receptor-activating peptides in vitro and in vivo. J Biol Chem 2002;277:45888–45903

—. COHEN SE, KOKKOTOU E, BIDDINGER SB, KONDO T, GEBHARDT R, KRATZCH J, MANTZOROS CS, KAHN CR. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knockout (LIRKO) mice. J Biol Chem 2007;282:23672–23678

—. MAIONE D, DI CARLO E, LI W, MUSIPANI P, MODESTI A, PETERS M, ROSE-JOHN S, DELLA ROCCA C, TRIPOLI M, LAZAROZZI D, TAUB R, SAVINO R, CILIBERTO G. Soluble IL-6 receptor: a modulator of leptin resistance. Metabolism 2005;54:308–310

—. BIDDLINGMAIER M, POSTEL-VINAY MC, WU Z, STRASBURGER CJ, ROSS BJ. Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology 2001;142:4389–4393

—. DURRLEMAN S, BOITZER B, BIDDLINGMAIER M, POSTEL-VINAY MC, WU Z, STRASBURGER CJ, ROSS BJ. Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology 2001;142:4389–4393

—. BIDDLINGMAIER M, POSTEL-VINAY MC, WU Z, STRASBURGER CJ, ROSS BJ. Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology 2001;142:4389–4393

—. TARTAGLIA LA. Dembski M, WENG X, DENG N, CULPPEPPER J, DEVOS R, RICHARDS GJ, CAMPFELD LA, CLARK FT, DEEDS J, MIUR C, SANKER S, MORIARTY A, MOORE KJ, SMUTKO JS, MAYS GG, WOOL EA, MONROE CA, TEPPER RI. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263–1273

—. MANTZOROS CS, TRIPOLI M, LASSOY D, TAUB R, SAVINO R, CILIBERTO G. Soluble IL-6 receptor: a modulator of leptin resistance. Metabolism 2005;54:308–310

—. MAIONE D, DI CARLO E, LI W, MUSIPANI P, MODESTI A, PETERS M, ROSE-JOHN S, DELLA ROCCA C, TRIPOLI M, LAZAROZZI D, TAUB R, SAVINO R, CILIBERTO G. Soluble IL-6 receptor: a modulator of leptin resistance. Metabolism 2005;54:308–310
48. Brabant G, Horn R, von zur Mühlen A, Mayr B, Wurster U, Heidenreich F, Schnabel D, Grüters-Kieslich A, Zimmermann-Belsing T, Feldt-Rasmussen U. Free and protein bound leptin are distinct and independently controlled factors in energy regulation. Diabetologia 2000;43:438–442

49. Lee SA, Kallianpur A, Xiang YB, Wen W, Cai Q, Liu D, Fazio S, Linton MF, Zheng W, Shu XO. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev 2007;16:2464–2470

50. Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003;88:2838–2843